ArticleThrombosis and haemostasis2012
Reverse engineering for new oral anticoagulants: non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban.
M LeviPubMed ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it